Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Xyrem Stories

2014-03-31 08:29:52

Defitelio®? (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®(?) (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive...

2014-02-26 20:22:14

DUBLIN, Feb. 26, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. -- Cowen and Company 34(th) Annual Healthcare Conference in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST / 1:00 p.m. GMT. Matt Young, senior vice president, corporate development, will provide an overview of the company and a business and financial update....

2014-02-21 08:25:31

Approximately 98 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered DUBLIN, Feb. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) for $57.00 per share and per ADS (without duplication for ordinary...

2014-01-13 08:28:21

Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments DUBLIN, Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the...

2014-01-06 16:27:51

DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 13, 2014 at 10:00 a.m. PST / 6:00 p.m. GMT. A live audio webcast of the...

2013-11-20 16:26:50

DUBLIN, Nov. 20, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its participation at the 25th Annual Piper Jaffray Healthcare Conference in New York, NY. Bruce C. Cozadd, chairman and chief executive officer, will provide a corporate overview on Tuesday, December 3, at 8:30 a.m. EST / 1:30 p.m. GMT. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website...

2013-11-01 08:27:06

DUBLIN, Nov. 1, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 2013 Credit Suisse Healthcare Conference in Phoenix, AZ. Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company at the conference on Tuesday, November 12, at 11:30 a.m. MST / 6:30 p.m. GMT. A live audio webcast of the presentation may be accessed from the Investors section of the...

2013-10-22 16:25:13

DUBLIN, Oct. 22, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss third quarter 2013 financial results. Interested parties may access the live audio...

2013-09-27 23:27:35

Historic FDA meeting on narcolepsy drug development brings narcolepsy community to FDA to offer candid and emotional remarks on how narcolepsy affects their lives, and on current treatment options. Silver Spring, MD (PRWEB) September 27, 2013 Narcolepsy Network, a national nonprofit organization supporting people with narcolepsy, joined dozens of others from the narcolepsy community at the FDA’s public meeting on narcolepsy drug development. The meeting was held on September 24 at FDA...

2013-09-19 12:29:00

Comprehensive patient survey documents delayed diagnosis and unmet medical needs for this devastating disease WORCESTER, Mass., Sept. 19, 2013 /PRNewswire-USNewswire/ -- On September 24, 2013, patients with narcolepsy and other stakeholders will gather at the Food & Drug Administration to provide direct input on drug development issues affecting nearly 200,000 Americans with narcolepsy. The meeting, fourth in a series of 20 mandated under a 2012 law, will be the first session dedicated...